EAGAN, MN — November 12, 2014
Exciting news for Biothera, as the biotechnology company’s leading clinical candidate Imprime PGG is selected by Informa and Kantar health as one of the Most Interesting Oncology Projects to Watch.
Some of the very rigorous criteria include: unmet medical need, market potential, diversity of indications, strong science, partnering opportunities, and potential for new opportunities beyond initial indications.
Biothera’s Senior Vice President and Medical Director, Richard Huhn, will present at the Skygenix World NSCLC Summit on January 27th 2015 in Boston
Imprime PGG has a unique mechanism of action. It is administered in conjunction with monoclonal antibodies that target the tumor and activate complement, a soluble blood protein, which coats the tumor cells and essentially flags them for attack. Imprime PGG binds directly to neutrophils and monocytes via Complement Receptor 3, which enables redirection of the killing capacity of the neutrophils and monocytes to the now flagged tumor cells. Read more about Imprime PGG here.